Category Archives: Avastin

On Disclosure, Transparency, and Firewalls: A Call for Uniform Standards

Posted on May 7, 2011 by Laura Newman

Since Patient POV was launched March 29, I have been struggling with how to deal with the issue of industry-supported patient advocacy groups. On Thursday, ProPublica released its paper: “Financial Ties Bind Medical Societies to Drug and Device Makers” with … Continue reading →

Posted in American Academy of Ophthalmology, Avastin, disclosure, Drug costs, firewalls, nonprofits, Parkinson's Disease Foundation, patient advocacy groups, transparency | Tagged , , , , | 9 Comments

What the Macular Degeneration Drug Trial Means

Posted on May 3, 2011 by Laura Newman

Age-related macular degeneration is a leading cause of vision loss and blindness. The advanced form of the disease affects 1.6 million people in the United States.  That’s why results from the first year of a two-year clinical trial that tested … Continue reading →

Posted in Age-related macular degeneration, Avastin, Blindness, Drug costs, Outcomes, Vision | Tagged , , | 8 Comments